CL2016003181A1 - Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas (divisional de sol. n° 360-13). - Google Patents

Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas (divisional de sol. n° 360-13).

Info

Publication number
CL2016003181A1
CL2016003181A1 CL2016003181A CL2016003181A CL2016003181A1 CL 2016003181 A1 CL2016003181 A1 CL 2016003181A1 CL 2016003181 A CL2016003181 A CL 2016003181A CL 2016003181 A CL2016003181 A CL 2016003181A CL 2016003181 A1 CL2016003181 A1 CL 2016003181A1
Authority
CL
Chile
Prior art keywords
vaccines
production
methods
zoster virus
varicella zoster
Prior art date
Application number
CL2016003181A
Other languages
English (en)
Inventor
David L Krah
Jill Dehaven
Jennifer A Kriss
Colleen M Barr
Mary Yagodich
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2016003181A1 publication Critical patent/CL2016003181A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2016003181A 2010-08-05 2016-12-12 Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas (divisional de sol. n° 360-13). CL2016003181A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37103810P 2010-08-05 2010-08-05

Publications (1)

Publication Number Publication Date
CL2016003181A1 true CL2016003181A1 (es) 2017-06-02

Family

ID=45556327

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013000360A CL2013000360A1 (es) 2010-08-05 2013-02-05 Virus varicela zoster inactivado; composicion farmaceutica que comprende una cantidad de dicho virus; metodos para preparar dicho virus; vacuna que comprende el virus; uso de la vacuna para tratar herpes zóster.
CL2016003181A CL2016003181A1 (es) 2010-08-05 2016-12-12 Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas (divisional de sol. n° 360-13).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013000360A CL2013000360A1 (es) 2010-08-05 2013-02-05 Virus varicela zoster inactivado; composicion farmaceutica que comprende una cantidad de dicho virus; metodos para preparar dicho virus; vacuna que comprende el virus; uso de la vacuna para tratar herpes zóster.

Country Status (23)

Country Link
US (3) US20120034267A1 (es)
EP (2) EP3363894A1 (es)
JP (2) JP2013535488A (es)
KR (3) KR20160060790A (es)
CN (1) CN103167880B (es)
AR (1) AR082577A1 (es)
AU (1) AU2011285749B2 (es)
BR (1) BR112013001946A2 (es)
CA (1) CA2806454A1 (es)
CL (2) CL2013000360A1 (es)
CO (1) CO6731067A2 (es)
EC (1) ECSP13012476A (es)
MX (1) MX343600B (es)
MY (1) MY158419A (es)
NZ (1) NZ606549A (es)
PE (1) PE20131336A1 (es)
PH (1) PH12013500133A1 (es)
RU (1) RU2633058C2 (es)
SG (1) SG187222A1 (es)
TW (1) TW201208698A (es)
UA (1) UA112970C2 (es)
WO (1) WO2012018973A1 (es)
ZA (1) ZA201300622B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041505A4 (en) 2013-09-05 2017-04-19 Merck Sharp & Dohme Corp. Methods of immunization with varicella zoster virus antigen
RU2651040C2 (ru) * 2016-08-08 2018-04-18 Федеральное государственное бюджетное учреждение "48 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации Вакцина оспенная инактивированная эмбриональная сухая таблетированная для орального применения "ТЭОВин" и способ ее получения
RU2637093C1 (ru) * 2016-12-20 2017-11-29 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы
CN107174658B (zh) * 2017-04-29 2020-11-27 安徽智飞龙科马生物制药有限公司 人用水痘病毒灭活疫苗及其制备方法
CN109453371A (zh) * 2018-11-23 2019-03-12 中国兽医药品监察所 一种羊痘、山羊传染性胸膜肺炎二联灭活疫苗及其生产方法
RU2700410C1 (ru) * 2019-05-20 2019-09-17 Федеральное государственное бюджетное учреждение науки "Национальный научный центр морской биологии им. А.В. Жирмунского" Дальневосточного отделения Российской академии наук (ННЦМБ ДВО РАН) Метод иммуноокрашивания биологического материала для конфокальной микроскопии
EP4076515A1 (en) 2019-12-16 2022-10-26 Intervet International B.V. Inactivated piscine orthoreovirus vaccine
WO2024191324A1 (ru) * 2023-03-13 2024-09-19 Олег Александрович ШИЛОВ Способ получения препарата вакцины из цельных вирусов или бактерий

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (es) 1974-03-12 1978-11-01
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
AU687355B2 (en) * 1992-07-17 1998-02-26 Merck Sharp & Dohme Corp. Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP1286706A2 (en) * 2000-05-17 2003-03-05 The American National Red Cross Gamma irradiation of protein-based pharmaceutical products
US6946098B2 (en) * 2001-08-10 2005-09-20 Clearant, Inc. Methods for sterilizing biological materials
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
CA2558586A1 (en) * 2004-03-05 2005-09-15 The Research Foundation For Microbial Diseases Of Osaka University Recombinant varicella-zoster virus
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
MY172788A (en) * 2008-08-01 2019-12-12 Gamma Vaccines Pty Ltd Influenza vaccines

Also Published As

Publication number Publication date
EP2600893A1 (en) 2013-06-12
PH12013500133A1 (en) 2013-03-11
AU2011285749B2 (en) 2014-07-31
US20150209424A1 (en) 2015-07-30
EP2600893A4 (en) 2014-01-22
NZ606549A (en) 2014-12-24
SG187222A1 (en) 2013-03-28
MX2013001434A (es) 2013-03-12
KR20130036062A (ko) 2013-04-09
CA2806454A1 (en) 2012-02-09
RU2633058C2 (ru) 2017-10-11
ECSP13012476A (es) 2013-04-30
UA112970C2 (uk) 2016-11-25
TW201208698A (en) 2012-03-01
CL2013000360A1 (es) 2014-03-28
PE20131336A1 (es) 2013-11-21
KR20160018828A (ko) 2016-02-17
CN103167880B (zh) 2016-05-18
EP3363894A1 (en) 2018-08-22
AR082577A1 (es) 2012-12-19
ZA201300622B (en) 2013-09-25
WO2012018973A1 (en) 2012-02-09
JP2013535488A (ja) 2013-09-12
RU2013109417A (ru) 2014-09-10
BR112013001946A2 (pt) 2016-05-24
US20120034267A1 (en) 2012-02-09
US20180318412A1 (en) 2018-11-08
MX343600B (es) 2016-11-10
CO6731067A2 (es) 2013-08-15
KR20160060790A (ko) 2016-05-30
CN103167880A (zh) 2013-06-19
MY158419A (en) 2016-10-14
AU2011285749A1 (en) 2013-01-31
JP2016053032A (ja) 2016-04-14

Similar Documents

Publication Publication Date Title
CL2016003181A1 (es) Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas (divisional de sol. n° 360-13).
IL262123A (en) Influenza virus vaccines and uses thereof
IL293362B1 (en) Broadly-neutralizing anti-hiv antibodies
IL232780A0 (en) Influenza virus vaccines and uses thereof
IL261204A (en) Influenza virus vaccines and their use
CO6950471A2 (es) Pirimidinas anilladas sustituidas y uso de las mismas
HUE053545T2 (hu) Humán immundeficiencia vírus semlegesítõ antitestek és eljárások alkalmazásukra
HUE037064T2 (hu) Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére
BR112015002755A2 (pt) derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico, método de modificação de derivado de ácido hialurônico e uso de derivados
HUE036220T2 (hu) Kinazolin származékok vírusfertõzések és további betegségek kezelésére
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
AP2015008634A0 (en) Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same
IL230618A0 (en) Inhibitors of influenza viruses replication, compositions comprising the same and uses thereof
BR112014017518A2 (pt) anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
HUE055505T2 (hu) Anti-CGRP készítmények és alkalmazásuk
BR112015002981A2 (pt) vacina estável em meio líquido, e, métodos para vacinação de um canino, e para fabricar a vacina estável em meio líquido
BR112013010186A2 (pt) vidros de silicato de lítio ou cerâmicas de vidro, método para produção dos mesmos e uso dos mesmos
HUE037125T2 (hu) Pirrolo-[3,2-D]pirimidin-származékok vírusfertõzések és egyéb betegségek kezelésére
EP2679683A4 (en) NEW VARICELLA ZOSTER VIRUSES AND WINDPOCK AND HERPES ZOSTER VIRUS VACCINE THEREOF
BR112012006404A2 (pt) derivados de di-hidropteridinona, processo de preparação e uso farmacêutico dos mesmos
BR112014029274A2 (pt) anticorpo isolado, composição farmacêutica, uso do anticorpo, método para tratar infecção rábica, kit para tratar infecção rábica, kit para detectar vírus rábico, ácido nucleico isolado, e, célula hospedeira.
CL2015001689A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
EP2828284A4 (en) JCV NEUTRALIZING ANTIBODIES
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
PL3022297T3 (pl) Stabilny genetycznie onkolityczny wirus rna, sposób jego wytwarzania i zastosowanie